Cancer in heart disease patients: what are the limitations in the treatment strategy?

Coronary artery bypass grafting in patients with malignancy: a single-institute case series of eight patients

Background

The surgical strategy among patients with malignancy and coronary artery disease (CAD) remains controversial. In this study, we present the experiences of coronary artery bypass grafting (CABG) in patients with malignancy and analyzed the treatment outcomes.

Methods

From January 2011 to October 2021, eight patients combined with coronary artery disease and malignancy, six of them with three-vessel disease and two with anterior descending branch lesions on coronary angiography. The age ranged from 54 to 73 years (61.8 ± 7.7years). Four patients underwent CABG and staging for surgical oncology, and 2 patients underwent CABG and surgical oncology simultaneously. Four patients underwent CABG procedure with cardiopulmonary bypass (on-pump CABG), and the other patients underwent the procedure without cardiopulmonary bypass (off-pump CABG). All patients were followed up for 3 to 96 months (40.4 ± 31.5 months) postoperatively.

Results

The mean number of grafts was 2.6 ± 1.1, there was no in-hospital death, postoperative myocardial infarction, and stroke. Among the eight patients, one patient received chemotherapy and radiation before bypass surgery, which occurred postoperatively pulmonary infection, and the rest of 7 patients had no major adverse cardiovascular events during follow-up periods.

Conclusion

Based on the results of the present study, simultaneous or staged CABG and oncologic surgery according to the TNM stage of the tumor and cardiac assessment is an effective treatment for patients with severe CAD combined with malignancy.

Cardio-oncology discipline: focus on the necessities in developing countries

Cardiovascular diseases constitute one of the main aetiologies of mortality among patients with cancer. Population ageing and cancer survival rate improvements have resulted in the coexistence of cardiovascular diseases and malignancies in an increasing number of patients. With the diversity in treatments and the introduction of new drug lines, multiple mechanisms of cardiovascular injury have been recognized in these patients. Cardio-oncology is an emerging entity introduced to provide a proper solution to the several challenges encountered in the management of patients with cancer and cardiac involvement. This review will assess the logical grounds for establishing a cardio-oncology unit, describe the main objectives and the detailed responsibilities in such systems, and outline the target population. Furthermore, the importance of research and appropriate data collection will be highlighted. Lastly, the special considerations and modifications required for setting up such centres in the developing countries are discussed.

How to manage patients in whom malignancy and infective endocarditis are associated: a review

Objective. Infective endocarditis (IE) is a potentially short-term lethal condition. An association with malignancy could complicate diagnostic and therapeutic decisions. The questions to be answered are: (1) which type of malignancies are encountered; (2) how often has the association between malignancy and IE been described, and (3) what are thus far the diagnostic and treatment strategies for patients with both conditions. Methods. A literature search from 2010 to 2018 has been performed with the focus on IE and cancer/malignancy/neoplasm, as well as with risk factors for adverse outcome, when cancer was included in the analysis. Results. An association between digestive, respiratory and hematologic malignancy with IE has been observed in four large databases. The most important mechanisms for this association are a "port of entry" and immune suppression. Sixteen studies dealt with the effect of short and mid-term cancer on the outcome of surgery of IE in these patients. No uniform management strategy could be identified. It seems that a malignancy does not alter the short-term outcome for IE, although referral to a tertiary cardiac center and surgical treatment are less common for patients with known malignancy. Conclusions. Although there is an association between malignancy and IE, no treatment strategy has yet been developed for these patients. Short-term outcome of IE is unaltered by cancer. In most papers, the effect of cancer on mid-term survival is only significant in a univariate analysis, without being a predictor. The results indicate that cardiac surgery for IE should not be withheld in patients in whom a treatable malignancy has been found.

Changes in ischemia-modified albumin in myocardial toxicity induced by anthracycline and docetaxel chemotherapy

This study aims to evaluate differences in myocardial toxicity induced by different chemotherapy regimens. Patients were divided into 2 groups: epirubicin (EPI) combined with cyclophosphamide (EC) group and docetaxel combined with cyclophosphamide (TC) group. Changes in electrocardiograph (ECG) and ischemia-modified albumin (IMA) were determined pre- and 1, 3, and 6 courses of postchemotherapy. After the first course of chemotherapy, there was no significant difference in ECG and abnormal IMA incidence rates between the TC groups and EC groups (P > .05). After the third course and at the end of the sixth course, ECG and abnormal IMA incidence rates in the EC group were significantly higher than in the TC group (P < .05). Besides, IMA values significantly increased with the increase in chemotherapy courses in the EC group; and the value of the postsixth course was significantly higher than in the pre- and postfirst and -third courses of chemotherapy. IMA value in the postsixth course in the TC group was significantly higher than that in the pre- and postfirst and -third courses of chemotherapy. In addition, IMA values at the postfirst and -third courses of chemotherapy in the EC group were significantly higher than in the TC group. Both EC and TC chemotherapy regimens were harmful to the myocardium, and the incidence rate of myocardial damage increased with the increase of cumulative dose. Besides, the degree of myocardial damage in EC group was significantly higher than in the TC group.